Breaking News, Collaborations & Alliances

CANbridge, WuXi Biologics Enter Partnership

To enable CANbridge to develop and commercialize a portfolio of biotherapeutics for the treatment of rare diseases

CANbridge Pharmaceutical Inc. and WuXi Biologics have formed a strategic partnership to enable CANbridge to develop and commercialize a portfolio of biotherapeutics for the treatment of rare diseases.  CANbridge expects to file the first Investigational New Drug (IND) application in a rare disease in China with the lead candidate from this program in 2019. CANbridge may also develop these therapeutics on a global basis going forward under an exclusive licensing agreement. WuXi Biologics is ex...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters